Acelyrin and Pliant Therapeutics, both of which are viewed as takeover targets for Kevin Tang’s Concentra Biosciences, each adopted a “poison pill” on Thursday morning.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback